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Objectives The study sought to describe the authors’ experience with mitral transapical transcatheter valve-in-valve implan-
tation (TVIV).
Background Increasing numbers of mitral biological prostheses are being implanted in clinical practice. Transcatheter
valve-in-valve implantation may be a lower risk alternative treatment for high-risk patients with mitral valve
degeneration.
Methods Twenty-three consecutive patients with severe mitral bioprosthetic valve dysfunction underwent transapical mi-
tral TVIV between July 2007 and September 2012. Bioprosthetic failure was secondary to stenosis in 6 (26.1%),
regurgitation in 9 (39.1%), and combined in 8 (34.8%) patients.
Results All patients were elderly (mean age 81  6 years) and at high-risk for conventional redo surgery (Society of
Thoracic Surgeons score 12.1  6.8%). Successful transapical mitral TVIV was accomplished in all patients
using balloon expandable valves (Edwards Lifesciences, Irvine, California) with no intraoperative major com-
plications. One (4.4%) major stroke and 6 (26.1%) major bleeds were reported during hospitalization. Mitral
transvalvular gradient significantly decreased from 11.1  4.6 mm Hg to 6.9  2.2 mm Hg following the
procedure (p  0.01). Intervalvular mitral regurgitation was absent (47.8%) or mild (52.2%) in all cases af-
ter mitral TVIV. No cases of transvalvular regurgitation were seen. All patients were alive on 30-day follow-
up. At a median follow-up of 753 days (interquartile range: 376 to 1,119 days) survival was 90.4%. One
patient underwent successful mitral TVIV reintervention at 2 months due to atrial migration of the trans-
catheter valve. All patients alive were in New York Heart Association functional class I/II with good pros-
thetic valve performance.
Conclusions Transcatheter transapical mitral valve-in-valve implantation for dysfunctional biological mitral prosthesis can be
performed with minimal operative morbidity and mortality and favorable midterm clinical and hemodynamic
outcomes. (J Am Coll Cardiol 2013;61:1759–66) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.058Transcatheter aortic valve replacement (TAVR) is a viable
option for selected high-risk patient with aortic stenosis
(1–6). Refinements in TAVR techniques and technology
are anticipated to further improve clinical outcomes. The
valve-in-valve procedure has emerged as clinically effective
in the vast majority of patients with degenerated biopros-
From St. Paul’s Hospital, University of British Columbia, Vancouver, British
Columbia, Canada. Drs. Cheung, Webb, Binder, Thompson, Wood, and Ye are
consultants to Edwards Lifesciences. Dr. Cheung has received consultant fees and is
part of the Speakers’ Bureau for Edwards Lifesciences. Dr. Webb is a consultant for
Edwards Lifesciences. Dr. Wood is a consultant for Edwards Lifesciences and St.
Jude Medical. Dr. Binder has received an unrestricted research grant from the Swiss
National Foundation. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.Manuscript received November 15, 2012; revised manuscript received December
20, 2012, accepted January 8, 2013.thetic aortic valves (7). Transcatheter mitral valve implan-
tation therapies are being developed but will require further
improvement before wide spread clinical application. Mitral
transcatheter valve-in-valve (TVIV) implantation into failed
mitral bioprostheses was first reported by our group in 2009,
followed by several other published series confirming feasi-
bility (8–11). Significant clinical impact can be anticipated
as the absolute number of failing mitral biological prostheses
continues to grow. A less invasive approach for mitral
rereplacement is desirable for this ever-expanding high-risk
elderly population.
We report on 23 consecutive patients with symptomatic
mitral biological valve dysfunction managed successfully by
mitral TVIV using Edwards SAPIEN type balloon expand-
able valves (Edwards Lifesciences, Irvine, California) via the
apex of the left ventricle (LV).
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Population. From July 2007 to
September 2012, 23 patients un-
derwent transapical mitral TVIV
in a single center (St. Paul’s Hos-
pital, Vancouver, Canada). All
patients had previous mitral valve
replacement (MVR) with bio-
logical valve prosthesis and were
evaluated by a multidisciplinary
heart team. The indications for
reoperative MVR generally fol-
lowed the American College of
Cardiology/American Heart As-
sociation guidelines for mitral valve
surgery (12). Patients deemed un-
suitable for conventional mitral
valve rereplacement were considered as potential candidates
for mitral TVIV. Written informed consents were obtained
from each patient. Data pertaining to baseline characteris-
tics, procedural details and outcomes were prospectively
entered into a dedicated database. Transthoracic echocardi-
ography (TTE) and clinical follow-up were performed
Abbreviations
and Acronyms
IQR  interquartile range
LV  left ventricle
MVR  mitral valve
replacement
NYHA  New York Heart
Association
TAVR  transcatheter
aortic valve replacement
TEE  transesophageal
echocardiogram
TTE  transthoracic
echocardiography
TVIV  transcatheter
valve-in-valve
Figure 1 Step-by-Step Transapical Mitral Valve-in-Valve Procedu
Positioning (A) and deployment (B to D) of a 26-mm Edwards SAPIEN XT valve (Edwardspre-operatively, at discharge, at 6 and 12 months, and then
annually post-procedure.
Procedure. An Edwards balloon expandable valve and
Ascendra transapical delivery system (Edwards Lifesciences)
were used in all cases. The first-in-human mitral TVIV was
performed by the implantation of a 26-mm Cribier-
Edwards equine valve through a 33-F Ascendra delivery
system. In all subsequent cases, the lower profile 26-F and
24-F Ascendra and Ascendra Plus delivery system were
employed to deliver the bovine Edwards SAPIEN or
SAPIEN XT valves (Edwards Lifesciences). Importantly,
the transcatheter heart valve was crimped on the balloon of
the Ascendra delivery system with the sewing cuff facing the
apex of the left ventricle (the opposite way respect the
transapical aortic valve implantation).
All operations were performed in a hybrid operating
room equipped with standby cardiopulmonary bypass
support. The technique of transapical mitral TVIV im-
plantation was described previously (8). Briefly, patients
underwent general anesthesia with single lumen intuba-
tion. A mini left anterior thoracotomy was performed at
the fifth or sixth intercostal space. Hemostatic control of
the LV apex was achieved by 2 octagonal pledgeted sutures. The
iences) into a degenerated 27-mm Carpentier-Edwards prosthesis in mitral position.re
Lifesc
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J-guidewire, followed by the introduction of a 7-F sheath. A
0.035’’ Amplatz Extra Stiff wire (Cook Medical, Blooming-
ton, Indiana) was exchanged by Seldinger technique, fol-
lowed by the introduction of the Ascendra delivery sheath.
Balloon mitral valvuloplasty of the bioprosthesis was utilized
only in the first patient, but subsequently not required.
Selection of an appropriately sized SAPIEN valve depended
on the internal diameter of the pre-existing biological mitral
prosthesis as reported by the manufacturer and by in-
traoperative transesophageal echocardiography. The
SAPIEN valve was placed extending 3 to 5 mm atrially
relatively to the mitral prosthetic sewing cuff, as guided by
transesophageal echocardiogram (TEE) and fluoroscopy
(Fig. 1). Cardiac motion and output was reduced by rapid
ventricular pacing at a rate of 160 to 200 beats/min. TEE
confirmed post-implant stability and valvular performance
(Figs. 2 and 3).
Figure 2 3D Transesophageal Echocardiogram Pre- and Post-Tr
Systolic and diastolic 3-D reconstruction of a degenerated 27-mm Carpentier-Edwards
valve deployed inside (Post).Definitions and statistical analysis. Procedural success
and complications were reported according to VARC-2
(Valve Academic Research Consortium) definitions (13).
Continuous variables are described as mean  SD and
median with interquartile range (IQR). Categorical vari-
ables are described by frequencies and percentages and a
paired Student t test was employed to compare continuous
variables. Survival at follow-up was calculated and presented
according to the Kaplan-Meier method. All analysis was
performed using the SPSS version 17.0 software (IBM,
Chicago, Illinois).
Results
From July 2007 to September 2012, 23 consecutive patients
underwent mitral transapical TVIV in our institution. Base-
line demographics of all patients are listed in Table 1. Mean
age was 81  6 years and 61% of patients were female. All
ut 1 had New York Heart Association (NYHA) functional
pical Mitral Valve-in-Valve Implantation
Edwards Lifesciences) and a 26-mm Edwards SAPIEN XT (Edwards Lifesciences)ansa
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Transapical Mitral Valve-in-Valve Implantation April 30, 2013:1759–66class III/IV heart failure symptoms (95.7%). All patients
were reviewed at multidisciplinary Transcatheter Valve
Rounds and turned down for conventional reoperative
MVR surgery by cardiologists and cardiac surgeons. The
calculated Society of Thoracic Surgeons risk score was
12.2  6.9%. The primary mechanisms of bioprosthetic
ailure were stenosis in 7 (30.4%), regurgitation in 9 (39.1%), and
Figure 3 Doppler Continuous Transesophageal Echocardiogram
Transvalvular gradient pre- and post-transcatheter mitral valve-in-vale implantation.
Baseline Characteristics (n  23)Table 1 Baseline Characteristics (n  23)
Age, yrs 81.1 5.8
Female 14 (60.9)
Diabetes 4 (17.4)
Peripheral vascular disease 7 (30.4)
Prior stroke/TIA 8 (34.8)
Prior CABG 10 (43.5)
Prior tricuspid intervention 4 (17.4)
COPD 6 (26.1)
CRF 13 (56.5)
Permanent AF 14 (60.9)
Prior PM 7 (30.4)
NYHA functional class III and IV 22 (95.6)
NYHA functional class II 1 (4.4)
Etiology of degeneration
Stenosis 7 (30.4)
Regurgitation 9 (39.1)
Mixed 7 (30.4)
Echocardiogram
Mean mitral gradient, mm Hg 11.1 4.6
MVA, cm2 1.2 0.7
LVEF, % 54.5 12.3
STS score, % 12.6 6.9
Values are mean  SD or n (%).
AF Atrial fibrillation; CABG coronary artery bypass graft surgery; COPD chronic obstructive
ulmonary disease; CRF  chronic renal failure; LVEF  left ventricular ejection fraction; MVA t
itral valve area; NYHA  New York Heart Association; PM  pacemaker; STS  Society of
horacic Surgeons; TIA  transient ischemic attack.ixed in 7 (30.4%) patients. No patient had significant
erivalvular regurgitation. A variety of mitral bioprosthesis
ere treated at a median of 10 years (IQR: 8 to 10 years)
ost-MVR. The manufacturer’s labeled size ranged from 23
o 31 mm. Transcatheter valves implanted included the
ribier-Edwards (n  1; 4.3%), SAPIEN (n  12; 52.2%),
nd SAPIEN XT (n  10; 43.5%) (Edwards Lifesciences).
izes were 23 mm in 5, 26 mm in 13, and 29 mm in 5
atients. Two other patients had combined native aortic
alve stenosis in addition to their mitral bioprosthetic
alvular dysfunction. Both patients underwent successful
ombined transapical TAVR and mitral TVIV procedures.
urther details of baselines characteristics of the patients are
isplayed in Table 2.
arly clinical outcomes. Device success was 100% by
ARC-2 definition. There were no cases of valve malposi-
ioning or embolization. Repeat balloon dilation was suc-
essfully performed in 1 patient (4.4%) because of the
resence of moderate intervalvular regurgitation without
omplications. No patient required mechanical circulatory
upport. The majority of the patients (n  20; 86.9%) were
xtubated in the operating room or shortly after in the
ardiac intensive care unit. Major bleeding occurred in 6
atients (26%). Reoperation for bleeding or tamponade was
ot required. One patient (4.4%) had an in-hospital major
troke and 2 patients (8.7%) had stage III acute kidney
njury by VARC-2, 1 requiring temporary renal replacement
herapy. One patient with pre-existing atrioventricular con-
uction disturbance required a permanent pacemaker inser-
ion on post-operative day 3. There was no intraprocedural
nd no 30-day mortality. The median length of stay in
ospital was 6 days (IQR: 5 to 8 days). The vast majority of
atients (65.2%) were discharged on single antiplatelet
herapy (aspirin 81 mg or clopidogrel 75 mg daily for
rtic va
t
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baseline chronic atrial fibrillation). Seven patients (30.4%)
were discharge on dual antiplatelet therapy for 6 months.
One patient with atrial fibrillation considered at high risk
for bleeding was discharged on warfarin alone.
Midterm clinical outcomes. Major outcomes at follow-up are
listed in Table 3. At a median follow-up of 753 days (IQR:
376 to 1,119 days), Kaplan-Meier survival rate was 90.4%,
with the longest follow-up of 1,448 days. The first patient
suffered a periprocedural cerebrovascular event, complicated
by nosocomial pneumonia and acute renal injury requiring
temporary renal replacement therapy. This patient had a
prolonged intensive care stay and died on post-operative day
45 with respiratory failure, despite renal and neurological
recovery. One other late death occurred 135 days post-
procedure from an unknown cause. An 83-year-old male
patient with ischemic cardiomyopathy (LV ejection fraction
30%), had previous coronary artery bypass grafting, MVR
with a 27 mm CE Perimount pericardial valve (Edwards
Lifesciences) and LV aneurysmectomy (Dor) procedure in
2004, experienced a readmission due to acute heart failure 2
Mitral Prosthesis CharacteristicsTable 2 Mitral Prosthesis Characteristics
Patients
Year
Operation
Timing
MVR-TVIV
(yrs) Mitral Prosthesis
Label S
Extern
Diame
(mm
Patient #1 1990 17 Carpentier-Edwards Porcine 25
Patient #2 1997 11 Carpentier-Edwards Porcine 27
Patient #3 1996 13 Carpentier-Edwards Porcine 27
Patient #4 2001 8 Medtronic Mosaic 25
Patient #5 2007 2 Medtronic Mosaic 25
Patient #6 1999 11 Carpentier-Edwards Porcine 29
Patient #7 2001 9 Medtronic Mosaic 27
Patient #8 1999 11 Carpentier-Edwards Porcine 25
Patient #9 2000 10 Medtronic Mosaic 23
Patient #10 2005 6 St Jude Medical Epic 29
Patient #11 2006 5 Carpentier-Edwards
Perimount
29
Patient #12 2004 7 Carpentier-Edwards
Perimount
27
Patient #13 2002 9 Carpentier-Edwards
Perimount
29
Patient #14 2002 8 Medtronic Mosaic 33
Patient #15 1998 11 Medtronic Mosaic 27
Patient #16 2000 11 Medtronic Mosaic 29
Patient #17 1995 14 Carpentier-Edwards Porcine 27
Patient #18 1999 13 Carpentier-Edwards
Perimount
23
Patient #19 2001 9 Carpentier-Edwards
Perimount
25
Patient #20 1998 13 Carpentier-Edwards Porcine 25
Patient #21 1996 16 Carpentier-Edwards Porcine 27
Patient #22 2003 9 Medtronic Mosaic 27
Patient #23 2004 6 Carpentier-Edwards
Perimount
31
CABG  coronary aortic bypass grafting; MVR  mitral valve replacement; SAVR  surgical ao
ranscatheter valve-in-valve.months after an uneventful mitral TVIV procedure with a26-mm SAPIEN prosthesis. The transthoracic echocardio-
gram showed 4- to 5-mm atrial migration of the SAPIEN
valve, leading to severe intervalvular regurgitation. A
second transapical mitral TVIV implantation with a 29-mm
Label Size
Internal
Diameter
(mm)
Others Cardiac
Operation
Type of
Dysfunction Type THV
Size
THV
(mm)
23 CABG Stenosis Cribier-Edwards 26
25 CABG Regurgitation Edwards SAPIEN 26
25 None Regurgitation Edwards SAPIEN 26
22.5 CABG Stenosis Edwards SAPIEN 23
22.5 SAVR and
myomectomy
Regurgitation Edwards SAPIEN 23
27 None Regurgitation Edwards SAPIEN 26
24 None Regurgitation Edwards SAPIEN 26
23 CABG Stenosis Edwards SAPIEN 23
20.5 CABG Mixed Edwards SAPIEN 23
TVR Regurgitation Edwards SAPIEN XT 26
28 CABG Stenosis Edwards SAPIEN XT 26
25 CABG Mixed Edwards SAPIEN XT 26
28 CABG and TVA Regurgitation Edwards SAPIEN XT 29
30 CABG and SAVR Regurgitation Edwards SAPIEN XT 29
24 CABG Mixed Edwards SAPIEN 26
26 None Mixed Edwards SAPIEN XT 29
25 None Mixed Edwards SAPIEN 26
22 TVA Stenosis Edwards SAPIEN XT 23
23 None Stenosis Edwards SAPIEN 26
23 CABG Mixed Edwards SAPIEN 26
25 SAVR Regurgitation Edwards SAPIEN XT 29
24 TVA Stenosis Edwards SAPIEN XT 26
29 SAVR Mixed Edwards SAPIEN XT 29
lve replacement; THV  transcatheter heart valve; TVA  tricuspid valve annuloplasty; TVIV 
Clinical Events, as EstimatedAccording to Kaplan-Meier MethodTable 3 Clinic l Ev nts, as EstimatedAccording to Kaplan-Meier Method
In-Hospital
Cumulative Event Rate
at Last Follow-Up
All-cause death 0 (0.0) 2 (9.6)
Cardiovascular death 0 (0.0) 1 (4.5)*
Myocardial infarction 0 (0.0) 0 (0.0)
Major stroke 1 (4.4) 1 (4.4)
Minor stroke 0 (0.0) 0 (0.0)
TIA 0 (0.0) 0 (0.0)
Life-threatening bleeding 0 (0.0) 0 (0.0)
Major bleeding 6 (26.1) 6 (26.1)
Minor bleeding 0 (0.0) 0 (0.0)
Reintervention 0 (0.0) 1 (4.4)
PM implantation 1 (4.4) 1 (4.4)
Values are n (%). *Unknown death, defined as cardiovascular according to Valve Academicize
al
ter
)Research Consortium definitions.
Abbreviations as in Table 1.
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no intervalvular regurgitation.
Clinical improvement in heart failure symptoms to
NYHA functional class I/II were observed in all but 1
patient at last follow-up (95.6%). One patient with com-
bined LV outflow tract obstruction from hypertrophic
obstructive cardiomyopathy had persistent NYHA func-
tional class III symptoms despite post-mitral TVIV alcohol
septal ablation and good prosthetic valve function.
TVIV valvular performance. All patients were assessed by
TTE prior to hospital discharge, at 6 months, 1 year, and
annually after TVIV. At discharge, a significant reduction in
prosthetic valvular regurgitation was seen in all patients;
there was no regurgitation in 11 (47.8%) and mild transval-
vular regurgitation in 12 (52.2%) (Fig. 4). The pre-operative
transvalvular gradient was reduced from 11.1  4.6 mm Hg
to 6.9  2.2 mm Hg (p  0.014) (Fig. 5).
At subsequent follow-up neither structural valve deterio-
ration nor worsening of paravalvular regurgitation was
observed. In 1 patient an atrial thrombus was detected on a
routine 1-month echocardiogram. This patient was asymp-
tomatic and was subsequently treated with systemic antico-
agulation with warfarin and aspirin. Complete resolution of
the atrial thrombus with normal prosthetic function was
confirmed at 1-year TTE (mean gradient 7.7  2.6 mm Hg).
No patient had moderate or severe mitral regurgitation at
last follow-up.
Discussion
Transcatheter transapical mitral valve-in-valve implantation
within failed biological prosthesis was initially demonstrated
to be technically possible by in vitro study. Antegrade access
to the mitral prosthesis can be obtained through either a
direct transatrial approach, first described by Walther et al.
Figure 4 Mitral Regurgitation
Degree of mitral regurgitation before and after transcatheter mitral
valve-in-valve implantation.(14) in animal study or via the venous system with trans-septal access into the left atrium. We reported our initial
attempts at mitral TVIV utilizing transseptal access (15)
and trans-atrial access through a right thoracotomy (8). We
found both approaches technically challenging, with diffi-
culty in achieving coaxial alignment of the valve stent to the
mitral prosthesis for proper valve deployment. However,
conversion of the transatrial procedure to a transapical
approach via a mini left thoracotomy proved successful and
all subsequent cases have been performed transapically. The
LV apex provides the most direct, shortest and co-axial
access to the mitral valve. Procedural success was achieved in
100% of cases, without access site complications, or proce-
dural mortality.
As the mitral valve is typically oriented toward the apex,
crossing the diseased prosthesis was generally accomplished
with relative ease. Fluoroscopy is most useful in cases where
the prosthesis incorporates a radiopaque sewing ring; ra-
diopaque stent posts are less helpful (Fig. 6). Fluoroscopic
positioning of the implant is best accomplished in a plane
perpendicular to the mitral valve, typically a 45° to 60° RAO
projection. TEE is generally very helpful, and crucial when
the bioprosthesis is radiolucent.
Selection of an appropriately sized implant remains con-
troversial. We generally oversize the pre-existing prosthesis
by a minimal of 10% according to the manufacturer’s
reported internal diameter to ensure secure anchoring of the
implant within the sewing ring and minimize paravalvular
regurgitation. Extreme oversizing is not desirable as a
severely underexpanded implant may result in a higher
transvalvular gradient, suboptimal leaflet coaptation, and
Figure 5 Transvalvular Gradient
Transvalvular gradient pre- and post-transcatheter mitral valve-in-valve
implantation.
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(9–11), in our series, the internal diameter of the previously
implanted bioprosthesis provided by the manufacturers was
the most important criteria for transcatheter valve sizing.
Prostheses with an internal diameter less than 21.5 mm
were treated with a 23-mm SAPIEN valve. A 26-mm valve
was chosen for internal diameters ranging from 21.5 to 24.5
mm. Finally, for diameters larger than 24.5 mm a 29-mm
valve was chosen.
Transesophageal echocardiography and multidetector
computed tomography were used to confirm the internal
diameter of the degenerated bioprosthesis as well as to
provide further insights on bioprosthesis features (e.g.,
thrombi, vegetations, calcifications). However, it should be
recognized that neither method has been validated in this
setting.
Pre-implantation balloon valvuloplasty was performed prior
Figure 6 Mitral Bioprosthesis at Fluoroscopy
Examples of fluoroscopic appearance of 3 different mitral bioprosthetic valves
(A) Carpentier-Edwards Porcine valve (Edwards Lifesciences); (B) SJM Epic tis-
sue valve (St. Jude Medical, St. Paul, Minnesota); (C) Medtronic Mosaic tissue
valve (Medtronic, Minneapolis, Minnesota).to TVIV in our first patient. Subsequently this pre-dilation wasavoided due to the potential risk of embolism and acute mitral
regurgitation.
Study limitations. The early and midterm clinical results
are encouraging with no 30-day mortality and a 1-year
survival of 91% in this high-risk cohort. Significant symp-
tomatic relief and functional improvement was observed in
the majority of our patients at follow-up. The hemodynamic
performance of the mitral implant was excellent with
acceptable residual mean gradients of 6.8  2.7 mm Hg; in
line with gradients reported with surgical mitral valve
bioprostheses (16), and little or no paravalvular regurgita-
tion and durability at follow-up. Structural valve dysfunc-
tion was not seen at a median follow-up of 753 days.
However, because these transcatheter valves incorporate
biological tissue, as with surgical bioprosthetic valves, even-
tual failure can be expected. The durability of these valve
stents remained unknown and will require continuing
surveillance.
Conclusions
Transcatheter transapical mitral valve-in-valve implantation
for dysfunctional biological mitral prosthesis can be per-
formed with minimal morbidity and low operative mortal-
ity. Clinical and hemodynamic outcomes were favorable at
short- and midterm follow-up. The transapical approach
appeared particularly well suited to mitral TVIV.
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